Home/Pipeline/MAB-22

MAB-22

Oncology

PreclinicalActive

Key Facts

Indication

Oncology

Phase

Preclinical

Status

Active

Company

Meitheal Pharmaceuticals

About Meitheal Pharmaceuticals

Meitheal Pharmaceuticals is a private, commercial-stage biopharma company focused on generic injectables and biosimilars. Leveraging a partnership-driven model, it has built a diverse pipeline and product portfolio targeting therapeutic areas such as anti-infectives, oncology, diabetes, fertility, and immunology. The company emphasizes robust manufacturing, steady supply, and rapid market response to address unmet needs and improve drug affordability. Its recent expansion into biosimilars with the acquisition of YUSIMRY® and launch of products like liraglutide injection signals a strategic growth phase.

View full company profile

Therapeutic Areas

Anti-Infective Oncology Immunology & Inflammation Fertility Diabetes

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active